



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/37959/2023

European Medicines Agency decision P/0085/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for danuglipron (EMEA-002944-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0085/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for danuglipron (EMA-002944-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pfizer Europe MA EEIG on 17 March 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 January 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for danuglipron, tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for danuglipron, tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for danuglipron, tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 - Brussels, Belgium.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/854239/2022
Amsterdam, 20 January 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002944-PIP02-22

Scope of the application

Active substance(s):

Danuglipron

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of obesity

Pharmaceutical form(s):

Tablet

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Europe MA EEIG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted for agreement to the European Medicines Agency on 17 March 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 25 April 2022.

Supplementary information was provided by the applicant on 14 October 2022. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of obesity

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- tablet, oral use, age-appropriate oral dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of obesity

2.1.1. Indication(s) targeted by the PIP

Adjuvant therapy in children and adolescents from 6 years to less than 18 years of age with obesity or overweight with at least one weight-related comorbidity.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

Age-appropriate oral dosage form

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate formulation suitable for oral use in the paediatric population from 6 years to less than 18 years of age.
Non-clinical studies	Not applicable
Clinical studies	Study 2 Multicentre randomised, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and efficacy of danuglipron in post-pubertal children and adolescents from 10 years to less than 18

	<p>years of age with obesity or overweight with at least one weight-related comorbidity.</p> <p>Study 3</p> <p>Multicentre randomised, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and efficacy of danuglipron in pre-pubertal children and from 6 years to less than 12 years of age with obesity or overweight with at least one weight-related comorbidity.</p>
Modelling and simulation studies	<p>Study 4</p> <p>Population-pharmacokinetic modelling and simulation study to select the dose of danuglipron to be used in post-pubertal children and adolescents from 10 years to less than 18 years of age with obesity or overweight with at least one weight-related comorbidity.</p> <p>Study 5</p> <p>Population-pharmacokinetic modelling and simulation and exposure-response study to further define the dose of danuglipron to be used in post-pubertal children and adolescents from 10 years to less than 18 years of age with obesity or overweight with at least one weight-related comorbidity.</p> <p>Study 6</p> <p>Population-pharmacokinetic modelling and simulation study to select the dose of danuglipron to be used in pre-pubertal children from 6 years to less than 12 years of age with obesity or overweight with at least one weight-related comorbidity.</p> <p>Study 7</p> <p>Population-pharmacokinetic modelling and simulation and exposure-response study to further define the dose of danuglipron to be used in pre-pubertal children from 6 years to less than 12 years of age with obesity or overweight with at least one weight-related comorbidity.</p>
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2034
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.